Volanesorsen is an antisense oligonucleotide indicated to treat familial chylomicronemia. Volanesorsen is an antisense oligonucleotide that binds to apoC-III mRNA to prevent its translation.
- Mechanism
- Curator reviewed · 3 references
Volanesorsen is an antisense oligonucleotide that binds to apoC-III mRNA, leading to its degradation, and preventing translation of apoC-III protein. Normally, apoC-III would inhibit triglyceride metabolism and hepatic clearance of chylomicrons. Preventing translation of apoC-III allows for metabolism and breakdown of these triglycerides and chylomicrons.
- Primary indication
- Volanesorsen is conditionally approved by the EMA as an adjunct to diet in adults with familial chylomicronemia, at high risk for pancreatitis, and who have had an inadequate response to diet and triglyceride lowering therapy.Curator reviewed · 1 structured indication
- First approval
- European Union, 2020
- Code names
- ISIS 304801
- Brand names
Resolves to
What you can answer from here — as of July 17, 2026
Which drugs share a target with Volanesorsen, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account